Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Researchers also found that about one-third of teens undergoing weight-loss surgery had a body mass index (BMI) of more than ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

European pharmaceutical giant Novo Nordisk (NVO) has struck a licensing deal with U.S. biotech firm Septerna (SEPN) to ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...